Skip to main content
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. — Investor Relations & Filings

Ticker · PCRX ISIN · US6951271005 LEI · 549300P56LERYBDHCF69 US Manufacturing
Open in API
Filings indexed 1,217 across all filing types
Latest filing 2019-06-25 M&A Activity
Country US United States of America
Listing US PCRX

About Pacira BioSciences, Inc.

https://www.pacira.com/

Pacira BioSciences, Inc. is a pharmaceutical company that develops, commercializes, and manufactures non-opioid pain management and regenerative health solutions. The company's mission is to provide alternatives to opioids by delivering innovative, precise, and targeted therapies. Its products and research pipeline address a diverse range of needs, including postsurgical, chronic, and musculoskeletal pain. Pacira is also focused on developing advanced solutions, including gene therapy, to address unmet needs in pain management.

Recent filings

Filing Released Lang Actions
8-K/A
M&A Activity Classification · 95% confidence The document is a Form 8-K/A (Amendment No. 1) filed with the SEC by Pacira BioSciences, Inc. It reports the completion of an acquisition (merger) and includes the historical financial statements of the acquired company (MyoScience) and pro forma condensed combined financial information. The document references the merger agreement and provides financial statements related to the merger. This type of filing is related to merger activity and acquisition disclosures. It is not a full annual report, earnings release, or other types of filings. The presence of merger agreement details and pro forma financials aligns with M&A Activity filings.
2019-06-25 English
FORM 3 SUBMISSION
Director's Dealing
2019-06-19 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 19, 2019, reporting the appointment of Max Reinhardt as President of Pacira BioSciences, Inc. The content focuses on the departure and appointment of a senior officer, including details of the employment agreement and compensation. There are no financial statements or earnings data presented. The primary subject is a management change announcement. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is 7302 characters, which is sufficient to contain detailed information about the management change. Therefore, the appropriate classification is MANG with high confidence.
2019-06-19 English
FORM 4 SUBMISSION
Director's Dealing
2019-06-13 English
FORM 4 SUBMISSION
Director's Dealing
2019-06-12 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Pacira BioSciences, Inc. It reports on the 2019 Annual Meeting of Stockholders held on June 4, 2019. The content includes details about the approval of the Amended and Restated 2011 Stock Incentive Plan, election of directors, ratification of the independent auditor, advisory votes on executive compensation, and voting results. The document primarily provides official results from shareholder votes at the Annual Meeting. It is not the full Annual Report, nor a proxy statement, but a current report disclosing voting outcomes and related corporate governance matters. Therefore, the filing best fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (6600 characters) and detailed voting results support this classification with high confidence.
2019-06-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.